Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
FROM THE WIRE · CNBC.COM
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive late-stage result strengthens Lilly's growth outlook in obesity treatment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly plans to file by year-end for US approval.
- 02The daily pill targets moderate-to-severe obstructive sleep apnea in adults with obesity.
- 03The late-stage trial showed the pill eases sleep apnea.